Fierce Biotech August 21, 2024
BioMarin Pharmaceutical is shaking up its leadership team, raiding Amgen for an R&D chief to replace a departing company veteran and pulling off the coup of signing a high-profile former Roche dealmaker.
The two people joining the company are Greg Friberg, M.D., and James Sabry, M.D., Ph.D. Friberg will take the title of chief research and development officer when he joins BioMarin at the end of September. The incoming executive spent 18 years at Amgen, rising to the position of vice president, global medical affairs, rare disease, but is now making the trip up the California coast to BioMarin.
Friberg is joining BioMarin to replace Hank Fuchs, M.D., who is retiring after 15 years at the company. Fuchs will stick...
Today's Sponsors
Today's Sponsor